Lysyl oxidase (LOX) down-regulation by TNFα: A new mechanism underlying TNFα-induced endothelial dysfunction

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 558-564

  Rodriguez C ^a   Alcudia, J F ^a   Martinez Gonzalez J ^a   Raposo, B ^a   Navarro, M A ^a   Badimon, L ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Atherosclerosis; Endothelial dysfunction; Lysyl oxidase; TNF

Indexed keywords

MESSENGER RNA; PROTEIN LYSINE 6 OXIDASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ANIMAL EXPERIMENT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN;

ANIMALS; AORTA; APOPTOSIS; CATTLE; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HUMANS; MALE; PROTEIN KINASE C; PROTEIN-LYSINE 6-OXIDASE; RATS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SUS SCROFA; TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 38349121602     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.002     Document Type: Article

References (33)

1. Mehta J.L., and Li D.Y. Inflammation in ischemic heart disease: response to tissue injury or a pathogenetic villain?. Cardiovasc Res 43 (1999) 291-299
2. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
3. Fiichtlscherer S., Rossig L., Breuer S., Vasa M., Dimmeler S., and Zeiher A.M. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 104 (2001) 3023-3025
4. Agnoletti L., Curello S., Bachetti T., et al. Serum from patients with severe heart failure down-regulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation 100 (1999) 1983-1991
5. Wang P., Ba Z.F., and Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol 266 (1994) H2535-H2541
6. Ferro T., Neumann P., Gertzberg N., Clements R., and Johnson A. Protein kinase C-alpha mediates endothelial barrier dysfunction induced by TNF-alpha. Am J Physiol Lung Cell Mol Physiol 278 (2000) L1107-L1117
7. Krasinski K., Spyridopoulos I., Kearney M., and Losordo D.W. In vivo blockade of tumor necrosis factor-alpha accelerates functional endothelial recovery after balloon angioplasty. Circulation 104 (2001) 1754-1756
8. Picchi A., Gao X., Belmadani S., et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 99 (2006) 69-77
9. Nystrom T., Nygren A., and Sjoholm A. Increased levels of tumour necrosis factor-alpha (TNF-alpha) in patients with Type II diabetes mellitus after myocardial infarction are related to endothelial dysfunction. Clin Sci (Lond) 110 (2006) 673-681
10. Mann D.L. Targeted anticytokine therapy and the failing heart. Am J Cardiol 95 (2005) 9C-16C
11. Kagan H.M., and Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 88 (2003) 660-672
12. Erler J.T., Bennewith K.L., Nicolau M., et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
13. Song Y.L., Ford J.W., Gordon D., and Shanley C.J. Regulation of lysyl oxidase by interferon-γ in rat aortic smooth muscle cells. Arterioscler Thromb Vasc Biol 20 (2000) 982-988
14. Maki J.M., Rasanen J., Tikkanen H., et al. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction and perinatal death in mice. Circulation 106 (2002) 2503-2509
15. Rodríguez C., Raposo B., Martínez-González J., Casani L., and Badimon L. Low density lipoproteins down-regulates lysyl oxidase in vascular endothelial cells and the arterial wall. Arterioscler Thromb Vasc Biol 22 (2002) 1409-1414
16. Raposo B., Rodríguez C., Martínez-González J., and Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and down-regulates LOX expression in vascular endothelial cells. Atherosclerosis 177 (2004) 1-8
17. Rodríguez C., Martínez-González J., Sánchez-Gómez S., and Badimon L. LDL down-regulates CYP51 in porcine vascular endothelial cells and in the arterial wall through a sterol regulatory element binding protein-2-dependent mechanism. Circ Res 88 (2001) 268-274
18. Rodríguez C., Raposo B., Martínez-González J., Llorente-Cortes V., Vilahur G., and Badimon L. Modulation of ERG25 expression by LDL in vascular cells. Cardiovasc Res 58 (2003) 178-185
19. Martínez-González J., Raposo B., Rodríguez C., and Badimon L. 3-Hydroxy-3-methylglutaryl coenzyme a reductase inhibition prevents endothelial NO synthase down-regulation by atherogenic levels of native LDLs: balance between transcriptional and posttranscriptional regulation. Arterioscler Thromb Vasc Biol 21 (2001) 804-809
20. García-Ramírez M., Martínez-González J., Juan-Babot J.O., Rodríguez C., and Badimon L. Transcription factor SOX18 is expressed in human coronary atherosclerotic lesions and regulates DNA synthesis and vascular cell growth. Arterioscler Thromb Vasc Biol 25 (2005) 2398-2403
21. Masaki T., Yoshimatsu H., Kakuma T., et al. Induction of rat uncoupling protein-2 gene treated with tumour necrosis factor alpha in vivo. Eur J Clin Invest 29 (1999) 76-82
22. Hornstra I.K., Birge S., Starcher B., Bailey A.J., Mecham R.P., and Shapiro S.D. Lysyl oxidase is required for vascular and diaphragmatic development in mice. J Biol Chem 278 (2003) 14387-14393
23. Huffman M.D., Curci J.A., Moore G., Kerns D.B., Starcher B.C., and Thompson R.W. Functional importance of connective tissue repair during the development of experimental abdominal aortic aneurysms. Surgery 128 (2000) 429-438
24. Sullivan C.J., Teal T.H., Luttrell I.P., Tran K.B., Peters M.A., and Wessells H. Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats. Physiol Genomics 23 (2005) 192-205
25. Pischon N., Darbois L.M., Palamakumbura A.H., Kessler E., and Trackman P.C. Regulation of collagen deposition and lysyl oxidase by tumor necrosis factor-alpha in osteoblasts. J Biol Chem 279 (2004) 30060-30065
26. Kishore R., Luedemann C., Bord E., Goukassian D., and Losordo D.W. Tumor necrosis factor-mediated E2F1 suppression in endothelial cells: differential requirement of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase signal transduction pathways. Circ Res 93 (2003) 932-940
27. Kishore R., Qin G., Luedemann C., et al. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest 115 (2005) 1785-1796
28. Min W., and Pober J.S. TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-kappa B and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways. J Immunol 159 (1997) 3508-3518
29. Pohlman T.H., and Harlan J.M. Human endothelial cell response to lipopolysaccharide, interleukin-1, and tumor necrosis factor is regulated by protein synthesis. Cell Immunol 119 (1989) 41-52
30. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 (2002) 477-492
31. Corredor J., Yan F., Shen C.C., et al. Tumor necrosis factor regulates intestinal epithelial cell migration by receptor-dependent mechanisms. Am J Physiol Cell Physiol 284 (2003) C953-C961
32. Pan S., An P., Zhang R., He X., Yin G., and Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis. Mol Cell Biol 22 (2002) 7512-7523
33. Grech A.P., Gardam S., Chan T., et al. Tumor necrosis factor receptor 2 (TNFR2) signaling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem 280 (2005) 31572-31581